Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$1.51 USD
-0.09 (-5.63%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
CYCC 1.51 -0.09(-5.63%)
Will CYCC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CYCC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CYCC
New Strong Buy Stocks for October 17th
Cyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's Why
CYCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release
Other News for CYCC
HTZ, CYCC and WORX among pre-market losers
CETX, ATNI and MNY among mid-day movers
12 Health Care Stocks Moving In Thursday's Intraday Session
MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers